Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collages gene COL2A1 mutation

Arthritis and Rheumatism

Volumn 42, Issue 1, 1999, Pages 39-45

  Bleasel, Jane F ^a   Poole, A Robin ^b   Heinegård, Dick ^c   Saxne, Tore ^c   Holderbaum, Daniel ^a   Ionescu, Mirella ^b   Jones, Paul ^a   Moskowitz, Roland W ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c LUND UNIVERSITY   (Sweden)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; BIOCHEMICAL MARKER; COLLAGEN TYPE 2; EPITOPE; KERATAN SULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CARTILAGE DEGENERATION; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN METABOLISM; RADIODIAGNOSIS; SCHOOL CHILD;

ADULT; AGED; BIOLOGICAL MARKERS; CARTILAGE; COBALT; COLLAGEN; EPITOPES; FAMILY HEALTH; FEMALE; HUMANS; MALE; MESOPORPHYRINS; MIDDLE AGED; OSTEOARTHRITIS;

EID: 0032922273     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199901)42:1<39::AID-ANR5>3.0.CO;2-Y     Document Type: Article

References (33)

1. Poole AR. Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis 1994;53:3-5.
2. Heinegård D, Saxne T. Molecular markers of processes in cartilage in joint disease. Br J Rheumatol 1991;30 Suppl:21-4.
3. Thonar EJ-MA, Shinmei M, Lohmander L. Body fluid markers of cartilage changes in osteoarthritis. Rheum Dis Clin North Am 1993;19:635-57.
4. Ala-Kokko L, Baldwin CT, Moskowitz RW, Prockop DJ. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc Natl Acad Sci U S A 1990;87:6565-8.
5. 519 to cysteine) in type II procollagen gene: a newly defined pathogenesis. Arthritis Rheum 1994;37:264-9.
6. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957;16:494-502.
7. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
8. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601-10.
9. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
10. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
11. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegård D, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995;34:306-10.
12. Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28: 1367-76.
13. Poole A, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. J Clin Invest 1994;94:25-33.
14. Månsson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis: difference between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
15. Thonar EJ-MA, Pachman LM, Lenz ME, Hayford J, Lynch P. Kuettner KE. Age related changes in the concentration of serum keratan sulphate in children. J Clin Chem Clin Biochem 1988;26: 57-63.
16. Eyre DR, Weis MA, Moskowitz RW. Cartilage expression of a type II collagen mutation in an inherited form of osteoarthritis associated with a mild chondrodysplasia. J Clin Invest 1991;87: 357-61.
17. Fertala A, Ala-Kokko L, Wiaderkiewicz R, Prockop DJ. Collagen II containing a Cys substitution for Arg-a 1-519: homotrimeric monomers containing the mutation do not assemble into fibrils but alter the self-assembly of the normal protein. J Biol Chem 1997;272:6457-64.
18. Petersson IF, Boegård T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis. Br J Rheumatol 1998;37:46-50.
19. Lohmander LS, Saxne T, Heinegård DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994;53:8-13.
20. Campion GV, McCrae F, Schnitzer TJ, Lenz ME, Dieppe PA, Thonar EJ-MA. Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum 1991;34:1254-9.
21. Katzenstein PL, Malcmud CJ, Pathria MN, Carter JR, Sheon RP, Moskowitz RW. Early-onset primary osteoarthritis and mild chondrodysplasia: radiographic and pathologic studies with an analysis of cartilage proteoglycan. Arthritis Rheum 1990;33:674-84.
22. Sweet MBE, Coelho A, Schnitzler CM, Schnitzer TJ, Lenz ME, Jakim I, et al. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum 1988;31:648-52.
23. Thonar EJ-M, Masuda K, Lenz ME, Hauselmann H, Kuettner KE, Manicourt DH. Serum markers of systemic disease processes in osteoarthritis. J Rheumatol 1995;22:68-70.
24. Spector TD, Woodward L, Hall GM, Hammond A, Williams A, Butler MG, et al. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Ann Rheum Dis 1992; 51:1134-7.
25. Muragaki Y, Mariman ECM, van Beersum SEC, Perälä M, van Mourik JBA, Warman ML, et al. A mutation in the gene encoding the α2 chain of the fibril-associated collagen IX, COL9A2, causes multiple epiphyseal dysplasia (EDM2). Nat Genet 1996;12:103-5.
26. Vikkula M, Mariman ECM, Lui VCH, Zhidkova NI, Tiller GE, Goldring MB, et al. Autosomal dominant and recessive osteochondrodysplasias associated with the (COL11A2) locus. Cell 1995;80: 431-7.
27. Briggs MD, Hoffman SMG, King LM, Olsen AS, Mohrenweiser H, Leror JG, et al. Pseudoachondroplasia and multiple epiphysial dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 1995;10:330-6.
28. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan in health and osteoarthritis. J Clin Invest 1992;90:2268-77.
29. Giant TT, Mikecz PJ, Roughley PJ, Buzas E, Poole AR. Age-related changes in protein-related epitopes of human articular cartilage proteoglycans. Biochem J 1986;236:71-5.
30. Shinmei M, Kobayashi T, Yoshihara Y, Samura A. Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinase, and metalloproteinases in osteoarthritis joint fluid. J Rheumatol 1995; 22:78-81.
31. Brandt KD, Braunstein EM, Visco DM, O'Connor B, Heck D, Albrecht M. Anterior (cranial) cruciate ligament transection in the dog: a bona fide model of osteoarthritis, not merely of cartilage injury and repair. J Rheumatol 1991;18:436-46.
32. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53-A:523-37.
33. Alley LM, Shao P, Ochs V, Shaffer K, Eyre DR. Matrix metalloproteinase-mediated release of immunoreactive telopeptides from cartilage type II collagen. Trans Orthop Res Soc 1998;23:450.